Literature DB >> 24124229

New connections between old pathways: PDK1 signaling promotes cellular transformation through PLK1-dependent MYC stabilization.

John T Cunningham1, Davide Ruggero.   

Abstract

Limited understanding of the functional link between multiple oncogenic pathways is a major barrier in the ongoing effort of cancer biologists to design an effective therapeutic approach to treat malignancies characterized by driver oncogenic network signals. In this issue of Cancer Discovery, Tan and colleagues elucidate a novel PDK1-PLK1-MYC signaling pathway connecting two fundamental oncogenic programs, phosphoinositide 3-kinase and MYC. They define the functional role for PDK1-PLK1-MYC signaling in cancer cell survival and tumor formation and show the therapeutic benefit of inhibiting PDK1 and PLK1 pharmacologically in cancer, tackling the most undruggable tumors defined by elevated levels of the MYC oncoprotein. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24124229      PMCID: PMC3857155          DOI: 10.1158/2159-8290.CD-13-0581

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  17 in total

1.  Targeting MYC dependence in cancer by inhibiting BET bromodomains.

Authors:  Jennifer A Mertz; Andrew R Conery; Barbara M Bryant; Peter Sandy; Srividya Balasubramanian; Deanna A Mele; Louise Bergeron; Robert J Sims
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

2.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

3.  Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland.

Authors:  Xiaoyan Wang; Melissa Cunningham; Xiaoli Zhang; Sara Tokarz; Bryan Laraway; Megan Troxell; Rosalie C Sears
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

Review 4.  Tumor suppressor functions of FBW7 in cancer development and progression.

Authors:  Zhiwei Wang; Hiroyuki Inuzuka; Jiateng Zhong; Lixin Wan; Hidefumi Fukushima; Fazlul H Sarkar; Wenyi Wei
Journal:  FEBS Lett       Date:  2012-03-21       Impact factor: 4.124

Review 5.  PI3K pathway alterations in cancer: variations on a theme.

Authors:  T L Yuan; L C Cantley
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

Review 6.  Targeting Polo-like kinase in cancer therapy.

Authors:  Yan Degenhardt; Thomas Lampkin
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

7.  Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

Authors:  Megan J Bywater; Gretchen Poortinga; Elaine Sanij; Nadine Hein; Abigail Peck; Carleen Cullinane; Meaghan Wall; Leonie Cluse; Denis Drygin; Kenna Anderes; Nanni Huser; Chris Proffitt; Joshua Bliesath; Mustapha Haddach; Michael K Schwaebe; David M Ryckman; William G Rice; Clemens Schmitt; Scott W Lowe; Ricky W Johnstone; Richard B Pearson; Grant A McArthur; Ross D Hannan
Journal:  Cancer Cell       Date:  2012-07-10       Impact factor: 31.743

8.  Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.

Authors:  Jongchan Kim; Isam-Eldin A Eltoum; Meejeon Roh; Jie Wang; Sarki A Abdulkadir
Journal:  PLoS Genet       Date:  2009-07-03       Impact factor: 5.917

9.  Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency.

Authors:  Maria Barna; Aya Pusic; Ornella Zollo; Maria Costa; Nadya Kondrashov; Eduardo Rego; Pulivarthi H Rao; Davide Ruggero
Journal:  Nature       Date:  2008-11-16       Impact factor: 49.962

10.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962

View more
  7 in total

1.  Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.

Authors:  Antonino Maria Spartà; Daniela Bressanin; Francesca Chiarini; Annalisa Lonetti; Alessandra Cappellini; Cecilia Evangelisti; Camilla Evangelisti; Fraia Melchionda; Andrea Pession; Alice Bertaina; Franco Locatelli; James A McCubrey; Alberto M Martelli
Journal:  Cell Cycle       Date:  2014-05-29       Impact factor: 4.534

Review 2.  Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer.

Authors:  Benjamin D Hopkins; Marcus D Goncalves; Lewis C Cantley
Journal:  Nat Rev Endocrinol       Date:  2020-03-03       Impact factor: 43.330

3.  PI3K and Inhibitor of Apoptosis Proteins Modulate Gentamicin- Induced Hair Cell Death in the Zebrafish Lateral Line.

Authors:  Heather Wiedenhoft; Lauren Hayashi; Allison B Coffin
Journal:  Front Cell Neurosci       Date:  2017-10-18       Impact factor: 5.505

4.  Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells.

Authors:  Dandan Li; John E Mullinax; Taylor Aiken; Hongwu Xin; Gordon Wiegand; Andrew Anderson; Snorri Thorgeirsson; Itzhak Avital; Udo Rudloff
Journal:  BMC Cancer       Date:  2018-07-31       Impact factor: 4.430

5.  Design, Synthesis and Biological Activity Evaluation of S-Substituted 1H-5-Mercapto-1,2,4-Triazole Derivatives as Antiproliferative Agents in Colorectal Cancer.

Authors:  Marius Mioc; Sorin Avram; Vasile Bercean; Ludovic Kurunczi; Roxana M Ghiulai; Camelia Oprean; Dorina E Coricovac; Cristina Dehelean; Alexandra Mioc; Mihaela Balan-Porcarasu; Calin Tatu; Codruta Soica
Journal:  Front Chem       Date:  2018-08-23       Impact factor: 5.221

6.  Mini-Review: PDPK1 (3-phosphoinositide dependent protein kinase-1), An Emerging Cancer Stem Cell Target.

Authors:  Bogdan Domrachev; Sitanshu Singh; Dandan Li; Udo Rudloff
Journal:  J Cancer Treatment Diagn       Date:  2021-04-30

7.  TCRP1 promotes NIH/3T3 cell transformation by over-activating PDK1 and AKT1.

Authors:  C Wang; H Liu; Q Qiu; Z Zhang; Y Gu; Z He
Journal:  Oncogenesis       Date:  2017-04-24       Impact factor: 7.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.